A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

January 5, 2018

Study Completion Date

January 5, 2018

Conditions
Severe Sepsis
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (16)

27710

Duke University Medical Center, Durham

30303

Pulmonary And Critical Care Of Atlanta, Atlanta

32610

University Of Florida, Gainesville

40536

University Of Kentucky, Lexington

43210

The Ohio State University, Columbus

61637

Osf Saint Francis Medical Center, Peoria

63110

Washington University School Of Medicine, St Louis

80204

Denver Health Medical Center, Denver

80909

Univ. Of Colorado Health, Colorado Springs

95817

Uc Davis Medical Center, Sacramento

98104

Harborview Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center (BIDMC), Boston

01199

Baystate Medical Center, Springfield

48109-5008

University of Michigan, Division of Acute Care Surgery, Ann Arbor

15261-2500

UPMC, Pittsburgh

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY